Abstract
ABSTRACTPaxlovid, a novel antiviral medication developed by Pfizer, has attracted considerable attention as a coronavirus disease 2019 therapeutic since it may be effective in treating the severe acute respiratory syndrome coronavirus type 2‐caused disease. Paxlovid is known as a combination therapy since it includes two agents, Nirmatrelvir and Ritonavir, which both are involved in the viral replication process inhibition. A further discussion of the molecular structure, pharmacokinetics, and pharmacodynamics of both components will help comprehend Paxlovid's mechanism of impact and effectiveness. High‐performance and spectroscopic methods, including high‐performance liquid chromatography (HPLC), infrared, and ultraviolet‐visible spectroscopy have been among the methods employed for compound identification, quantification, and structural elucidation. Bioanalytical methods have also made a significant contribution to the evaluation of Paxlovid's pharmacokinetic parameters, bioavailability, and metabolism in biological matrices. LC‐tandem mass spectrometry (LC‐MS/MS) is widely employed for the quantification of Paxlovid and its metabolites in plasma, serum, and other biological samples. This study brings forth an overview of the characteristics and properties of Paxlovid along with analytical and bioanalytical methods employed for its assessment and quantification.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
